Identification of Novel STAT3 Dimerization Inhibitor Through Structure-Based Virtual Screening for Cancer Management
Abstract
Background: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that controls cell proliferation, differentiation, angiogenesis, and immunological responses. In many human malignancies, abnormal STAT3 activation promotes tumor growth via oncogenic gene expression, resulting in tumor malignancy. Many drugs with clinically authorized analogues that are used as STAT3 inhibitors for cancer therapy have several drawbacks in terms of stability and toxicity.
Methods: This study used PyRx 0.8 tool to screen the Traditional Chinese Medicine (TCM) database of about 32,364 commercially available natural compounds in order to identify new STAT3 inhibitors. Physicochemical and ADME properties of selected compounds were estimated using Datawarrior and SwissADME.
Result: The top 20 compounds were initially chosen based on their strong binding affinities with STAT3. Lipinski and Vaber tools were used to filter the top 20 compounds, yielding the top 6 compounds. The compounds ZINC85542844, ZINC4098720, ZINC85543599, ZINC85593523, ZINC85593528, and ZINC85593537 were passed through these filters. These compounds were found to interact with active site STAT3 residues and have several amino acid interactions in common with the control compound (STX0119).
Conclusion: This study suggests that the compounds ZINC85542844, ZINC4098720, ZINC85543599, ZINC85593523, ZINC85593528, and ZINC85593537 could be used as a lead for the development of novel STAT3 inhibitors. However, further experimental validation is required to optimized them as STAT3 inhibitors.
Keywords: STAT3; Transcription factor; Natural compounds; Cancer; Virtual screening
Full Text:
PDFReferences
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, (2011); 144(5): 646-674.
Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nature Reviews Cancer, (2002); 2(10): 740-749.
Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, (2012); 489(7414): 155-159.
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology, (2007); 7(1): 41-51.
Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: A double edged sword. Cytokine, (2017); 98: 42-50.
Masciocchi D, Gelain A, Villa S, Meneghetti F, Barlocco D. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Medicinal Chemistry, (2011); 3(5): 567-597.
Lavecchia A, Di Giovanni C, Cerchia C. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert Opinion on Therapeutic Patents, (2014);
(4): 383-400.
Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Current Medicinal Chemistry, (2011); 18(16): 2359-2375.
Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Letters, (2007); 251(2): 199-210.
Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Annals of the New York Academy of Sciences, (2009); 1171: 59-76.
Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Molecular Interventions, (2011); 11(1): 18-26.
Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature, (1998); 394(6689): 145-151.
Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. Molecular and Cellular Biology, (1998); 18(5): 2553-2558.
Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, (2000); 19(56): 6613-6626.
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics, (2003); 22(2): 151-185.
Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, (2019); 24(3): 773-780.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.
Yadav DK, Kumar S, Choi EH, Chaudhary S, Kim MH. Computational Modeling on Aquaporin-3 as Skin Cancer Target: A Virtual Screening Study. Frontiers in Chemistry, (2020); 8: 250.
Khanam R, Hejazi, II, Shahabuddin S, Bhat AR, Athar F. Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors. Journal of Pharmaceutical Analysis, (2019); 9(2): 133-141.
Matsuno K, Masuda Y, Uehara Y, Sato H, Muroya A, et al. Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Medicinal Chemistry Letters, (2010); 1(8): 371-375.
Tarique M, Ahmad S, Malik A, Ahmad I, Saeed M, et al. Correction to: Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis. Molecular and Cellular Biochemistry, (2022); 477(2): 645.
Stanzione F, Giangreco I, Cole JC. Use of molecular docking computational tools in drug discovery. Progress in Medicinal Chemistry, (2021); 60: 273-343.
Brogi S. Computational Approaches for Drug Discovery. Molecules, (2019); 24(17): 3061.
Chang MW, Ayeni C, Breuer S, Torbett BE. Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One, (2010); 5(8): e11955.
Sayed Murad HA, M MR, Alqahtani SM, B SR, Alghamdi S, et al. Molecular docking analysis of AGTR1 antagonists. Bioinformation, (2023); 19(3): 284-289.
Atanasov AG, Zotchev SB, Dirsch VM; International Natural Product Sciences Taskforce; Supuran CT. Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery, (2021); 20(3): 200-216.
DOI: http://dx.doi.org/10.62940/als.v11i2.2975
Refbacks
- There are currently no refbacks.